Accounts Payable

3 Months Ended

Mar. 31, 2023

Accounts Payable

Accounts Payable

5.            Accounts Payable

As of March 31, 2023, current liabilities included accounts payable of $0.8 million, comprised primarily of expenses related to drug manufacturing, development and testing services of $0.5 million and clinical trial expenses of $0.3 million. As of December 31, 2022, current liabilities included accounts payable of $0.7 million, comprised primarily of expenses related to drug manufacturing, development and testing services of $0.6 million and legal and patent fees of $0.1 million.